Effect of TGP on T cell immune function in patients with oral lichen planus
吕冬梅
Abstract
吕冬梅
Abstract
Objective To study the effect of total glucosides of paeonia( TGP)on T cell immune function in patients with oral lichen planus. Methods Ninety patients with oral lichen planus were randomly divided into two groups, the control group and the observation group,with 45 patients in each group. The patients in the control group were given local injection of triamcinolone acetonide,once every week for 4 weeks. While the patients in the observation group were given TGP,0. 6 g every time,3 times/day,for 3 months,on the basis of the treatment in the control group. The serum levels of CD3+,CD4+,CD8+ and CD4+/CD8+ in the two groups were detected before treatment,at 1 month and 3 months after treatment. Results After 3 months of treatment,the total effective rate in the control group was 80%,and 93. 3% in the observation group,there was significant difference(P﹤0. 05). There was no significant difference in the serum levels of CD3+,CD4 +,CD8 + and CD4 +/CD8 + between the two groups before treatment( P﹥0. 05 ). After 1 month of treatment,there was no significant difference in the serum levels of CD3 +,CD4 +,CD8 + and CD4 +/CD8+ of the two groups,compared with those before treatment( P ﹥0. 05 ). After 3 months of treatment,there was no significant difference in the serum levels of CD3 +, CD4+,CD8+ and CD4+/CD8+ in the control group,compared with those before treatment(P﹥0. 05),but there were significant differences in the serum levels of CD3+,CD4+,CD8+ and CD4+/CD8+ in the observation group,compared with those before treatment(P﹤0. 05). Conclusions TGP can significantly improve the T cell immune function in patients with oral lichen planus,so as to improve the condition. Key words: Oral lichen planus; Total glucosides of paeonia; Immune function
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Objective To study the effect of total glucosides of paeonia( TGP)on T cell immune function in patients with oral lichen planus. Methods Ninety patients with oral lichen planus were randomly divided into two groups, the control group and the observation group,with 45 patients in each group. The patients in the control group were given local injection of triamcinolone acetonide,once every week for 4 weeks. While the patients in the observation group were given TGP,0. 6 g every time,3 times/day,for 3 months,on the basis of the treatment in the control group. The serum levels of CD3+,CD4+,CD8+ and CD4+/CD8+ in the two groups were detected before treatment,at 1 month and 3 months after treatment. Results After 3 months of treatment,the total effective rate in the control group was 80%,and 93. 3% in the observation group,there was significant difference(P﹤0. 05). There was no significant difference in the serum levels of CD3+,CD4 +,CD8 + and CD4 +/CD8 + between the two groups before treatment( P﹥0. 05 ). After 1 month of treatment,there was no significant difference in the serum levels of CD3 +,CD4 +,CD8 + and CD4 +/CD8+ of the two groups,compared with those before treatment( P ﹥0. 05 ). After 3 months of treatment,there was no significant difference in the serum levels of CD3 +, CD4+,CD8+ and CD4+/CD8+ in the control group,compared with those before treatment(P﹥0. 05),but there were significant differences in the serum levels of CD3+,CD4+,CD8+ and CD4+/CD8+ in the observation group,compared with those before treatment(P﹤0. 05). Conclusions TGP can significantly improve the T cell immune function in patients with oral lichen planus,so as to improve the condition. Key words: Oral lichen planus; Total glucosides of paeonia; Immune function
Key concepts: CD8, Triamcinolone acetonide, Medicine, Significant difference, Gastroenterology, Internal medicine, CD3, Immune system